Forming Collaborations With the Physical Therapy Team in Cancer Treatment

Commentary
Video

Physical therapists may play a key role in patient care before, during, and after treatment for cancer, according to Alison Ankiewicz, DPT, PT.

CancerNetwork® visited Mary’s Place by the Sea, a cancer treatment center in Neptune Township, New Jersey, to speak with Alison Ankiewicz, DPT, PT, to learn more about how oncology clinicians can best collaborate with pelvic floor physical therapists to elevate the quality of care for patients undergoing treatment for cancer. Specifically, Ankiewicz highlighted the indicators or symptoms that medical oncologists should search for that may indicate a need for specialized care.

According to Ankiewicz, co-owner of Inner Dynamics Physical Therapy: Pelvic Health and Wellness Center and a board member of Mary’s Place by the Sea, many medical and radiation oncologists may not recognize the services of physical therapists. She emphasized how pelvic health physical therapists should be included in the multidisciplinary team, describing the assistance they can provide before, during, and after a patient’s care.

Ankiewicz indicated the role that physical therapists can play to mitigate tissue changes stemming from medication, hormonal changes following therapy, and other effects from surgery. Regarding abdominal surgeries, specifically, she noted that her work can help improve the mobility and motility of tissue following treatment, thereby restoring the function of muscles within the pelvic region.

Transcript:

Unfortunately, I feel a lot of oncologists and radiation oncologists are not aware of our services, so I feel like it is important for them to take note that pelvic health physical therapy should be part of that multidisciplinary team. [They should be] getting their patients to us prior to treatments and then even during treatments and posttreatments. Again, whether it is related to tissue changes from the medication, hormonal changes, or surgery, we should be part of the team. When we have abdominal surgeries or perhaps hysterectomies, we often work with scar tissue and improving the mobility and motility of our tissue, which will restore the function of our muscles within the pelvic region. Getting started sooner [rather] than later is important for these physicians to realize.

Recent Videos
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
A substantial portion of patients who received daratumumab in the AQUILA study were able to delay disease progression to active multiple myeloma.
Results showed no “deleterious reactions” with chlorotoxin-directed cellular therapy in a small cohort of patients with recurrent glioblastoma.
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A novel CAR T-cell therapy may bind with more avidity, rather than affinity, to glioblastoma cells, said Michael Barish, PhD.
Using chlorotoxin as a targeting element may bind to more glioblastoma cells than other targeting entities, according to Michael Barish, PhD.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
Related Content